Select Your Region
Global
Find participating medical centers and current study status in each of them
Find participating medical centers
-
Home
-
Search Results
- ZEBRHA 3
Clinical Trial of NXT007 for the Prophylactic Treatment of Hemophilia A in Infants and Children
-
Hemophilia -
Hemophilia A
- For Medical Professional
-
Download
Basic Details
Sponsor
Hoffmann-La Roche
Phase
Phase 3
Trial Identifier
NCT07838194, BO45888, 2026-526103-29-00
Condition
Hemophilia A
Official Title
A Multicenter, Open-Label, Single-Arm, Phase III Clinical Trial to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of NXT007 Prophylaxis in Pediatric Patients With Hemophilia A
Study Summary
The purpose of this study is to evaluate the efficacy, safety, pharmacokinetics and pharmacodynamics of NXT007 prophylaxis in pediatric patients aged 0 to 11 years with severe or moderate congenital hemophilia A without factor VIII inhibitors or congenital hemophilia A of any severity (severe, moderate, and mild) with inhibitors (emicizumab-naïve and treated). Patients with hemophilia A aged ≥12 to <18 years old with a body weight of <40 kilograms (kg) are also able to participate.
Eligibility Criteria
All
≥0 Years & ≤ 17 Years
No
Inclusion Criteria
- Age <12 years at the time of signing Informed Consent Form; or age ≥12 and <18 years with body weight <40 kg
- Diagnosis of severe (Factor VIII coagulation protein activity [FVIII:C] <1 International Unit per decilitre [IU/dL]) or moderate (FVIII:C between ≥1 IU/dL and ≤5 IU/dL) congenital hemophilia A (HA) with or without inhibitors against factor VIII (FVIII)
- For potential participants with moderate HA without inhibitors, fulfillment of at least one of the following criteria: Current prophylaxis with long-term prophylaxis intention due to a severe bleed phenotype; For those not treated with prophylaxis: at least one traumatic joint or critical muscle bleed in the last 6 months or ≥2 spontaneous bleeds/year or 5 bleeds/year, including traumatic bleeds; Signs of joint degeneration compatible with hemophilic arthropathy (e.g., subchondral bone changes or the presence of synovitis) as assessed by any imaging assessment (e.g., ultrasound, MRI, radiograph); Bleeding at a critical site (e.g., intracranial).
- Diagnosis of mild (FVIII:C between >5 IU/dL and <40 IU/dL) congenital hemophilia A with chronic FVIII inhibitors, defined as documented FVIII inhibitor (≥0.6 BU/mL or ≥1.0 BU/mL only for laboratories with a historical sensitivity cutoff for inhibitor detection of 1.0 BU/mL) and chronic reduction of endogenous baseline FVIII:C to <5 IU/dL for ≥12 months
- Documentation of the details of prophylactic and episodic FVIII treatment, bypassing agent (BPA) treatment, emicizumab prophylaxis treatment, and the number and type of bleeding episodes for at least the last 6 months prior to screening if appropriate
- For potential participants taking on-demand treatments prior to study entry: agreement to move to a prophylaxis treatment with NXT007
- Adequate renal, hepatic, and hematologic function, as defined in the protocol
Exclusion Criteria
- Sensitivity to any of the study investigations, or components thereof, or drug or other allergy that, in the opinion of the investigator, contraindicates participation in the study
- Use of systemic immunomodulators (e.g., interferon or rituximab) at the time of enrollment or planned use during the study, except for antiretroviral therapy to treat HIV
- Refusal to accept plasma-derived and/or blood product transfusion support in an emergency scenario
- History or conditions, other than HA, which may indicate hypo- or hypercoagulopathy risk
- Planned surgery (excluding minor procedures, such as non-molar tooth extraction or incision and drainage) during the study
- History of ventricular dysrhythmias or risk factors for ventricular dysrhythmias such as structural heart disease (e.g., severe left ventricular systolic dysfunction, left ventricular hypertrophy)
- Any serious medical condition or abnormality in clinical laboratory tests that precludes an individual's safe participation in and completion of the study
This page summarises information from public registry websites, such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc. To learn more about this study, see the For Medical Professional tab or visit one of those websites.
The information is taken directly from public registry websites such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc., and has not been edited.
Results Disclaimer
Explore related studies
For the latest version of this information please go to www.forpatients.roche.com